Browsing by Author "Wang, Lu"
Now showing 1 - 2 of 2
Results Per Page
Sort Options
- ItemOpen AccessAnti-Inflammatory and Cytoprotective Actions of Hydrogen Sulfide: Translation to Therapeutics(Antioxidants & Redox Signaling, 2015-04-15) Wallace, John L.; Blackler, Rory W.; Chan, Melissa V.; Da Silva, Gabriela J.; Elsheikh, Wagdi; Flannigan, Kyle L.; Gamaniek, Iulia; Manko, Anna; Wang, Lu; Motta, Jean-Paul; Buret, Andre G.Significance: There is a rapidly expanding body of evidence for important roles of hydrogen sulfide in protecting against tissue injury, reducing inflammation, and promoting repair. There is also growing evidence that H2S can be successfully exploited in drug development. Recent Advances: H2S synthesis and degradation are regulated in circumstances of inflammation and injury so as to promote repair and re-establish homeostasis. Novel H2S-releasing drugs exhibit enhanced anti-inflammatory and pro-restorative effects, while having reduced adverse effects in many tissues. Critical Issues: H2S is a pleiotropic mediator, having effects on many elements in the inflammatory cascade and promoting the resolution of inflammation and injury. It also contributes significantly to mucosal defence in the gastrointestinal tract, and in host defence against infection. There is strong evidence that novel, H2S-based therapeutics are safe and effective in animal models, and several are progressing through human trials. Future Directions: A better understanding of the physiological and pathophysiological roles of H2S continues to be restrained by the lack of simple, reliable methods for measurement of H2S synthesis, and the paucity of highly selective inhibitors of enzymes that participate in endogenous H2S synthesis. On the other hand, H2S donors show promise as therapeutics for several important indications. Antioxid. Redox Signal. 22, 398–410.
- ItemOpen AccessIntegrative analysis of clinicopathological features defines novel prognostic models for mantle cell lymphoma in the immunochemotherapy era: a report from The North American Mantle Cell Lymphoma Consortium(2023-12-16) Vose, Julie M.; Fu, Kai; Wang, Lu; Mansoor, Adnan; Stewart, Douglas; Cheng, Hongxia; Smith, Lynette; Yuan, Ji; Qureishi, Hina N.; Link, Brian K.; Cessna, Melissa H.; Barr, Paul M.; Kahl, Brad S.; Mckinney, Matthew S.; Khan, Nadia; Advani, Ranjana H.; Martin, Peter; Goy, Andre H.; Phillips, Tycel J.; Mehta, Amitkumar; Kamdar, Manali; Crump, Michael; Pro, Barbara; Flowers, Christopher R.; Jacobson, Caron A.; Smith, Sonali M.; Stephens, Deborah M.; Bachanova, Veronika; Jin, Zhaohui; Wu, Shishou; Hernandez-Ilizaliturri, Francisco; Torka, Pallawi; Anampa-Guzmán, Andrea; Kashef, Farshid; Li, Xing; Sharma, Sunandini; Greiner, Timothy C.; Armitage, James O.; Lunning, Matthew; Weisenburger, Dennis D.; Bociek, Robert G.; Iqbal, Javeed; Yu, Guohua; Bi, ChengfengAbstract Background Patients with mantle cell lymphoma (MCL) exhibit a wide variation in clinical presentation and outcome. However, the commonly used prognostic models are outdated and inadequate to address the needs of the current multidisciplinary management of this disease. This study aims to investigate the clinical and pathological features of MCL in the immunochemotherapy era and improve the prognostic models for a more accurate prediction of patient outcomes. Methods The North American Mantle Cell Lymphoma Project is a multi-institutional collaboration of 23 institutions across North America to evaluate and refine prognosticators for front-line therapy. A total of 586 MCL cases diagnosed between 2000 and 2012 are included in this study. A comprehensive retrospective analysis was performed on the clinicopathological features, treatment approaches, and outcomes of these cases. The establishment of novel prognostic models was based on in-depth examination of baseline parameters, and subsequent validation in an independent cohort of MCL cases. Results In front-line strategies, the use of hematopoietic stem cell transplantation was the most significant parameter affecting outcomes, for both overall survival (OS, p < 0.0001) and progression-free survival (PFS, p < 0.0001). P53 positive expression was the most significant pathological parameter correlating with inferior outcomes (p < 0.0001 for OS and p = 0.0021 for PFS). Based on the baseline risk factor profile, we developed a set of prognostic models incorporating clinical, laboratory, and pathological parameters that are specifically tailored for various applications. These models, when tested in the validation cohort, exhibited strong predictive power for survival and showed a stratification resembling the training cohort. Conclusions The outcome of patients with MCL has markedly improved over the past two decades, and further enhancement is anticipated with the evolution of clinical management. The innovative prognostic models developed in this study would serve as a valuable tool to guide the selection of more suitable treatment strategies for patients with MCL.